Equillium Logo.png
Equillium to Host Business Update Call on February 26
February 19, 2019 16:07 ET | Equillium
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with...
Equillium Logo.png
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
February 07, 2019 08:08 ET | Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Equillium_Transparent-300px.png
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
December 19, 2018 08:06 ET | Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
November 15, 2018 16:07 ET | Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present at Investor Conferences in November 2018
November 01, 2018 16:07 ET | Equillium, Inc.
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Announces Pricing of Initial Public Offering
October 12, 2018 08:25 ET | Equillium, Inc.
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune...